Primary entity: ACP-105Also known as: ACP105; ACP 105Class: performance-adjacent literacy (see page)Cluster: Performance-adjacent

ACP-105 is a lesser-known investigational selective androgen receptor modulator appearing in research-chemical and forum demand next to better-known SARMs. It is not a peptide, not FDA-approved, and falls under WADA’s SARM / other anabolic agents prohibitions even when a specific brand name is less famous than ostarine.

Important chemistry callout:

ACP-105 is not a peptide. It is a SARM-class AR ligand. Obscurity ≠ legality in sport.

Regulatory / sport status at a glance (as of early Oct 2026):

Not FDA-approved. SARMs as a class are prohibited under S1.2; athletes must not assume an unnamed boutique SARM is allowed.

Key takeaways

  • Not a peptide — investigational SARM.
  • Not FDA-approved; thin public clinical footprint vs ostarine/LGD.
  • WADA SARM-class risk
  • No dosage charts.

Questions this page answers

Next questions we answer on this page (curiosity / AI-gap map):

  1. What is ACP-105?
  2. Aliases
  3. Classification
  4. What it is NOT
  5. Mechanism
  6. Evidence ladder
  7. What has been studied
  8. Safety literacy
  9. Regulatory & WADA
  10. Why no dosages
  11. Related
  12. Who for / not for

Who is this profile for — and who is it not for?

For: readers who found ACP-105 on a research-chem menu and need class/sport literacy.

Not for: cycle designers.

What is ACP-105?

ACP-105 is a research SARM with less mainstream clinical publicity than enobosarm or LGD-4033. Lower fame does not mean lower anti-doping or quality risk.

Chemistry classInvestigational SARM
Peptide?No
Public clinical footprintThinner than ostarine/LGD
U.S. approvalNot approved
SportSARM-class WADA risk

Also known as

  • ACP-105 / ACP105 — research code.
  • Mis-tags: “ACP peptide.”
Myth callout — “Obscure SARMs aren’t tested.”

Anti-doping labs expand panels continuously. Class bans and metabolite methods catch many analogues. Assume risk.

How is ACP-105 classified?

Investigational SARM — unapproved. Performance-adjacent literacy set.

What is ACP-105 not?

ACP-105 is not…Why that matters
A peptideSARM
FDA-approvedNo
“Safe because obscure”False
Something we doseRefusal

How is ACP-105 thought to work?

Androgen-receptor selective modulation — standard SARM framing.

What human vs animal vs label evidence exists?

Evidence typeWhat exists (summary)Maturity
Human clinicalLimited public late-stage evidence vs major SARMsNone/Human thin
PreclinicalAR modulator research modelsAnimal/Cell
Approved labelNoneNone

Prefer “thin public record” over invented trial claims.

What has ACP-105 been studied for?

Preclinical/research SARM characterization. Not an approved indication set.

What safety topics come up?

Apply SARM class literacy (HPTA, lipids, liver case-report themes, product identity risk). Sparse specific human PI. Not medical advice.

What is ACP-105's regulatory status?

  • U.S.: Not FDA-approved; SARM supplement sales targeted by FDA class warnings.
  • WADA: SARM class under S1.2 — confirm ACP-105 / metabolites on GlobalDRO
  • Gray market: High identity uncertainty.

Why doesn't this page include a dosage chart?

Refused.

Related lab literacy

Not peptide reconstitution.

Frequently asked questions

Is ACP-105 a peptide?

No. It is a SARM.

Is it FDA approved?

No.

Is it safer because fewer people talk about it?

No. Obscurity is not a safety or legality feature.

WADA status?

Treat as SARM-class prohibited — verify GlobalDRO.

Reminder

Not a peptide, not FDA-approved, WADA SARM-class risk. Disclaimer..

Sources

The sources below were checked against PubMed, DailyMed, or the official agency page on November 10, 2026 (America/Phoenix). Links go to the publisher, PubMed, or the agency record.

  1. Analytical / ADME Fijałkowska O, et al. First multifaceted ADME profile of ACP-105 (CAS: 1048998-11-3): a novel non-steroidal selective androgen receptor modulator used as doping in sports-integrative in silico toxicological studies for clinical and forensic toxicology purposes. Arch Toxicol. 2025. doi:10.1007/s00204-025-04170-5. PMID: 40928534. Analytical/ADME work, not a human efficacy trial.
  2. Regulatory U.S. Food and Drug Administration. FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults. Accessed November 10, 2026.
  3. Anti-doping World Anti-Doping Agency. The World Anti-Doping Code International Standard Prohibited List 2026. Accessed November 10, 2026. Confirm the current list and GlobalDRO before relying on sport status. The 2026 list prohibits SARMs as a class under S1.2 and names several examples; ACP-105 was not listed by that exact name on the page we checked. Check GlobalDRO for the specific substance.
Written by
Peptide Tutorials Staff — a group of independent researchers & writers (not clinicians)
Published · Updated
Oct 7, 2026 · Oct 7, 2026 · Regulatory and sport-status wording checked November 10, 2026 against current FDA labels and the 2026 WADA Prohibited List · How we source & update

Educational disclaimer: Educational only. ACP-105 is not a peptide and is not FDA-approved. No dosing or buy links. We don't sell peptides. Read our full disclaimers.